1. Home
  2. SKYE vs SYNX Comparison

SKYE vs SYNX Comparison

Compare SKYE & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

N/A

Current Price

$0.85

Market Cap

6.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
SYNX
Founded
2012
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.0M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
SKYE
SYNX
Price
$1.18
$0.85
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $68.00
N/A
AVG Volume (30 Days)
★ 98.4K
20.5K
Earning Date
11-24-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.65
52 Week High
$11.68
$1.95

Technical Indicators

Market Signals
Indicator
SKYE
SYNX
Relative Strength Index (RSI) 44.62 40.56
Support Level $0.26 $0.65
Resistance Level $1.66 $1.08
Average True Range (ATR) 0.20 0.08
MACD -0.00 -0.01
Stochastic Oscillator 62.05 26.49

Price Performance

Historical Comparison
SKYE
SYNX

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.

Share on Social Networks: